The novel anti-epileptic drug lacosamide targets two proteins -voltage-gated sodium channels and collapsin response mediator protein 2 (CRMP-2) -suggesting dual modes of action for lacosamide. We recently identified the neurite outgrowth and axonal guidance protein CRMP-2 as a novel partner and regulator of the presynaptic N-type voltage-gated Ca 2+ channel (CaV2.2) [Brittain et al., J. Biol. Chem. 284: 31375-31390 (2009)]. Here we examined the effects of lacosamide on voltage-gated Ba 2+ channels. Lacosamide did not affect Ba 2+ currents via N-and P/Q-channels in rat hippocampal neurons or L-type Ca 2+ channels in a mouse CNS neuronal cell line, respectively. N-type Ba 2+ currents, augmented by CRMP-2 expression, were also unaffected by acute or chronic lacosamide exposure. These results establish that the anti-epileptic mode of action of lacosamide does not involve these voltage-gated Ca 2+ channels.
introduction
Epilepsy is a serious medical condition characterized by seizures that result from spontaneous disturbances of the brain's normal electrical activity [1] . To combat two hallmarks of seizure generation -hyperexcitability of neurons and hypersynchrony of neural circuits -an arsenal of antiepileptic drugs (AEDs) have been developed. These AEDs act by potentiating inhibitory pathways within the central nervous system, inhibiting excitatory glutamatergic pathways, or inhibiting excessive neuronal firing [2] . [3, 4] .
Preclinical studies have identified two targets of LCM's actions. Lacosamide exerts a unique action on its presumed pharmacotherapeutic target, the voltage-gated sodium channels (VGSCs), by selectively enhancing the transition to a slow-inactivated state of the channel [3, 5, 6] . This ability to preferentially block the electrical activity of neurons that are chronically depolarized compared with those at more normal resting potentials sets LCM apart from classical VGSC-targeted AEDs such as carbamazepine, phenytoin, and lamotrigine [6] . Lacosamide's second target, as identified in proteomic and radioligand binding studies [3] , is the collapsin response mediator protein 2 (CRMP-2). Using a combined chemical and proteomics approach, Kohn and colleagues showed enantioselective LCM labeling of expressed as well as endogenous brain CRMP-2 [7] . Neither of these reports, however, addressed the mechanism of this interaction, nor did it address any additional pathways that could be affected by LCM's interaction with CRMPs.
CRMPs (also known as UNC-33-like proteins (Ulip), dyhropyriminidase-related protein (DRP), TOAD (turned on after division) and TUC (TOAD/Ulip/DRP)), are a family of five intracellular phosphoproteins implicated in neurite outgrowth and axonal guidance [8] [9] [10] . While highest during development, in the adult, CRMPs are expressed in brain regions capable of axonal outgrowth, neurogenesis, and synaptic rearrangements [10] . Such rearrangements of synaptic connectivity and aberrant neuronal growth have been observed in epilepsy [11] . At least two studies have reported altered CRMP-2 levels in epilepsy.
The first showed a decrease in CRMP-2 levels in brains from patients with mesial temporal lobe epilepsy that was refractory to treatment [12] .
The second reported decreased CRMP-2 levels in thalamuses of mice with absence seizures [13] . However, the mechanism by which CRMPs contribute to the pathophysiology of epilepsy is unclear. We hypothesize that LCM, by binding to CRMP-2, may prevent the aberrant synaptic connectivity and/or rearrangements seen in epilepsy. Lacosamide's interaction with CRMP-2 associated proteins can influence the development/progression of epilepsy.
We recently identified a direct interaction between CRMP-2 and N-type voltage-gated Ca 2+ channels (CaV2.2) that led to increased Ca 2+ current density via increased surface CaV2.2 expression which, together with CRMP-2-mediated increase in synaptic vesicle recycling, translated into an increased neurotransmitter release [14] . These results positioned CRMP-2 as a novel modulator of presynaptic release. While the roles of Ca 2+ in transmitter release [15] [16] [17] [18] and Ca 2+ dysregulation in epilepsy [19, 20] 
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Chemicals and Solutions
All reagents were purchased from Sigma studies [27] and approximately 5-fold the reported value for half-maximal inhibition of spontaneous excitatory postsynaptic currents and inhibitory postsynaptic currents [28] .
The N-type calcium channel blocker omegaconotoxin GVIA (w-CTX) and the P/Q-type calcium channel blocker omega-agatoxin IVA (w-Aga) were purchased from Alomone Labs (Jerusalem, Israel). with P/Q-type channels supporting ~25% [14, 30] and R-type supporting less than 3% A majority amount (~60%) of the Ba 2+ current in these neurons was conducted via CaV2.2 as assessed from the block observed upon perfusion of the N-type selective blocker w-conotoxin GVIA (1 mM), while ~85-90% could be blocked by concomitant application of w-conotoxin GVIA and the P/Q-type blocker w-Agatoxin IVA (500 nM: Figure 1C Figure 1A ) as has been reported for T-type currents [31, 32] . Second, no appreciable current is present at -30 mV, a voltage at which T-type currents have reached their peak [31, 32, 34] . Third, less than 20% of neurons express 2-3 pA/pF of T-type current [35] , which is at most one-fifteenth of the total peak N-and P/Q-type (i.e. non-L-type) current observed in our experiments and within the noise to be confidently assessed as T-type. Moreover, in a published review of LCM's preclinical properties, it was reported that 100 mM does not affect low-voltage activated T-type calcium channels in cortical neurons [28] . As Nifedipine has been reported to partially block T-type currents [26] , we cannot completely rule out the possibility that a small fraction of currents in our recordings could be due to T-type. However, as there was no difference in current densities of LCM-treated neurons in the presence or absence of Nifedipine, a contribution of T-type currents, if any, is likely to be negligible.
results

Lacosamide does not affect N-
We also tested the effects of LCM on steadystate activation and inactivation of Ba 2+ channel gating ( Figure 1D , E). The steady-state activation of Ba 2+ channels in control and LCM-treated neurons was described by the Boltzmann relation. As shown in current density in hippocampal neurons [22] .
Consistent with these previous findings, we observed a significant increase of ~58% in Ba Table 2 . . Peak currents were normalized to cell capacitance. There were no differences in Ba 2+ current density between the two conditions at all voltages tested (p > 0.05, Student's t-test). (B) Peak current density (pA/pF) measured at 0 mV was similar between CRMP-2 overexpressing neurons treated with 0.01% MPL (black bar) or 300 µM LCM (white bar)(n=7 each). As a reference, the peak current density of EGFP-expressing neurons (from Figure 1 12.9 ± 1.9
LCM 300 µM, 30 min -13.5 ± 2.9 (4) 11.1 ± 2.5 (4) -25.8 ± 3.9 (4) 12.2 ± 2.8
LCM 300 µM, 3 h -15.2 ± 1.5 (9) 10.1 ± 1.5 (9) -27.8 ± 1.9 (9) 12.5 ± 1.8
LCM 300 µM, 24 h -14.5 ± 2.9 (10) 9.5 ± 2.9 (10) -26.5 ± 2.4 (10) 12.1 ± 2.8 (10) LCM 300 µM, 72 h a -16.3 ± 1.1 (7) 8.1 ± 0.9 (7) -28.8 ± 2.5 (4) 15.8 ± 2.9 (4) Figure 2E ).
Peak tetrodotoxin-sensitive Na + currents from these neurons were blocked by ~65±9% (n=4)
following bath application of LCM ( Figure 2F) currents in a catecholaminergic cell line (CAD) [36] . CAD cells were chosen for these studies as they are easily amenable to genetic manipulation, are of neuronal origin, and express only L-type Ca 2+ channels [36] . Inward Ba 2+ currents that typically inactivated almost completely were observed in these cells ( Figure 3A) . As reported earlier [36] , the threshold for activation of These results indicate that LCM does not affect the current density or biophysical properties of L-type Ca 2+ currents. CRMP-2 expression and CRMP-2-mediated neuritogenesis are upregulated upon application of the neurotrophic factor glial cell line-derived neurotrophic factor (GDNF) [40] which has been shown to suppress seizures in animal models of epilepsy [41] , suggesting a link between CRMP-2 expression and epilepsy. at potentials more positive than -60 mV, peak current achieved at -30 mV, rapid inactivation, slow deactivation, contribution to 'window currents' which can engender membrane bistability), they can support rthymic, highfrequency activity thus making them useful targets in chronic pain [50] . It is under these pain conditions where LCM may become relevant to T-type channel activity. LCM has already been shown to be useful in muscle pain [51] , tumor-and chemotherapy-induced cancer pain [52] , and animal models of chronic inflammatory pain [53] .
discussion
4.2 CRMP-2 expression in epilepsy and other pathophysiologies CRMP proteins have been implicated in both developmental and adult neurological diseases [10] . Protein levels of CRMP-2 are significantly reduced in an animal model of epilepsy [13] and in human patients with mesial temporal lobe epilepsy [12] . Decreased levels of CRMP-2 have also been found in patients with Down's Syndrome, Alzheimer's disease, psychiatric disorders (schizophrenic, bipolar disorder or major depression disorder) [10] , and neuronal ceroid lipofuscinosis -a childhood neurodegenerative disorder [54] . In contrast, increased CRMP-2 levels have been reported in an animal model of chronic mild stress [55] , hyperalgesia [56] , traumatic brain injury and cerebral ischemia, and in nerve regeneration [57] . The overexpression of CRMP-2 in our hippocampal culture system results in at most a three-fold change in CRMP-2 protein (not shown) which is well within the range of changes reported in these pathophysiological
conditions. This change in CRMP-2 elicited increases hippocampal axonal length (not shown) but does not affect Ca 2+ channels.
In conclusion, our results support the contention that LCM does not affect N-, P/Q-and L-type calcium channels. This is an important conclusion in light of the findings of more than one target of action of LCM (i.e., Na + channels and CRMP-2), one of which has been linked to regulation of calcium channel activity [22, 29] 
